Impact	O
on	O
health	O
-	O
related	O
quality	O
of	O
life	O
deterioration	O
-	O
free	O
survival	O
of	O
a	O
first	O
-	O
line	O
therapy	O
combining	O
[P1]	O
nab	O
-	O
paclitaxel	O
[P2]	O
plus	O
either	O
gemcitabine	O
or	O
simplified	O
leucovorin	O
and	O
fluorouracil	O
for	O
patients	O
with	O
metastatic	O
pancreatic	O
cancer	O
:	O

Impact	O
on	O
health	O
-	O
related	O
quality	O
of	O
life	O
deterioration	O
-	O
free	O
survival	O
of	O
a	O
first	O
-	O
line	O
therapy	O
combining	O
nab	O
-	O
paclitaxel	O
plus	O
either	O
[P1]	O
gemcitabine	O
[P2]	O
or	O
simplified	O
leucovorin	O
and	O
fluorouracil	O
for	O
patients	O
with	O
metastatic	O
pancreatic	O
cancer	O
:	O

Impact	O
on	O
health	O
-	O
related	O
quality	O
of	O
life	O
deterioration	O
-	O
free	O
survival	O
of	O
a	O
first	O
-	O
line	O
therapy	O
combining	O
nab	O
-	O
paclitaxel	O
plus	O
either	O
gemcitabine	O
or	O
simplified	O
[P1]	O
leucovorin	O
and	O
fluorouracil	O
[P2]	O
for	O
patients	O
with	O
metastatic	O
pancreatic	O
cancer	O
:	O

Impact	O
on	O
health	O
-	O
related	O
quality	O
of	O
life	O
deterioration	O
-	O
free	O
survival	O
of	O
a	O
first	O
-	O
line	O
therapy	O
combining	O
[P1]	O
nab	O
-	O
paclitaxel	O
[P2]	O
plus	O
either	O
gemcitabine	O
or	O
simplified	O
leucovorin	O
and	O
fluorouracil	O
for	O
patients	O
with	O
metastatic	O
pancreatic	O
cancer	O
:	O

Impact	O
on	O
health	O
-	O
related	O
quality	O
of	O
life	O
deterioration	O
-	O
free	O
survival	O
of	O
a	O
first	O
-	O
line	O
therapy	O
combining	O
nab	O
-	O
paclitaxel	O
plus	O
either	O
[P1]	O
gemcitabine	O
[P2]	O
or	O
simplified	O
leucovorin	O
and	O
fluorouracil	O
for	O
patients	O
with	O
metastatic	O
pancreatic	O
cancer	O
:	O

Impact	O
on	O
health	O
-	O
related	O
quality	O
of	O
life	O
deterioration	O
-	O
free	O
survival	O
of	O
a	O
first	O
-	O
line	O
therapy	O
combining	O
nab	O
-	O
paclitaxel	O
plus	O
either	O
gemcitabine	O
or	O
simplified	O
[P1]	O
leucovorin	O
and	O
fluorouracil	O
[P2]	O
for	O
patients	O
with	O
metastatic	O
pancreatic	O
cancer	O
:	O

Impact	O
on	O
health	O
-	O
related	O
quality	O
of	O
life	O
deterioration	O
-	O
free	O
survival	O
of	O
a	O
first	O
-	O
line	O
therapy	O
combining	O
[P1]	O
nab	O
-	O
paclitaxel	O
[P2]	O
plus	O
either	O
gemcitabine	O
or	O
simplified	O
leucovorin	O
and	O
fluorouracil	O
for	O
patients	O
with	O
metastatic	O
pancreatic	O
cancer	O
:	O

Impact	O
on	O
health	O
-	O
related	O
quality	O
of	O
life	O
deterioration	O
-	O
free	O
survival	O
of	O
a	O
first	O
-	O
line	O
therapy	O
combining	O
nab	O
-	O
paclitaxel	O
plus	O
either	O
[P1]	O
gemcitabine	O
[P2]	O
or	O
simplified	O
leucovorin	O
and	O
fluorouracil	O
for	O
patients	O
with	O
metastatic	O
pancreatic	O
cancer	O
:	O

Impact	O
on	O
health	O
-	O
related	O
quality	O
of	O
life	O
deterioration	O
-	O
free	O
survival	O
of	O
a	O
first	O
-	O
line	O
therapy	O
combining	O
nab	O
-	O
paclitaxel	O
plus	O
either	O
gemcitabine	O
or	O
simplified	O
[P1]	O
leucovorin	O
and	O
fluorouracil	O
[P2]	O
for	O
patients	O
with	O
metastatic	O
pancreatic	O
cancer	O
:	O

France	O
3	O
Boulevard	O
Fleming	O
25030	O
Besançon	O
France	O
Impact	O
on	O
health	O
-	O
related	O
quality	O
of	O
life	O
deterioration	O
-	O
free	O
survival	O
of	O
a	O
first	O
-	O
line	O
therapy	O
combining	O
[P1]	O
nab	O
-	O
paclitaxel	O
[P2]	O
plus	O
either	O
gemcitabine	O
or	O
simplified	O
leucovorin	O
and	O
fluorouracil	O
for	O
patients	O
with	O
metastatic	O
pancreatic	O
cancer	O
:	O

France	O
3	O
Boulevard	O
Fleming	O
25030	O
Besançon	O
France	O
Impact	O
on	O
health	O
-	O
related	O
quality	O
of	O
life	O
deterioration	O
-	O
free	O
survival	O
of	O
a	O
first	O
-	O
line	O
therapy	O
combining	O
nab	O
-	O
paclitaxel	O
plus	O
either	O
[P1]	O
gemcitabine	O
[P2]	O
or	O
simplified	O
leucovorin	O
and	O
fluorouracil	O
for	O
patients	O
with	O
metastatic	O
pancreatic	O
cancer	O
:	O

France	O
3	O
Boulevard	O
Fleming	O
25030	O
Besançon	O
France	O
Impact	O
on	O
health	O
-	O
related	O
quality	O
of	O
life	O
deterioration	O
-	O
free	O
survival	O
of	O
a	O
first	O
-	O
line	O
therapy	O
combining	O
nab	O
-	O
paclitaxel	O
plus	O
either	O
gemcitabine	O
or	O
simplified	O
[P1]	O
leucovorin	O
and	O
fluorouracil	O
[P2]	O
for	O
patients	O
with	O
metastatic	O
pancreatic	O
cancer	O
:	O

In	O
this	O
context	O
,	O
based	O
on	O
the	O
phase	O
II	O
AFUGEM	O
clinical	O
trial	O
,	O
we	O
report	O
the	O
impact	O
on	O
HRQoL	O
of	O
a	O
first	O
-	O
line	O
therapy	O
combining	O
[P1]	O
nab	O
-	O
paclitaxel	O
[P2]	O
plus	O
either	O
gemcitabine	O
or	O
sLV5FU2	O
in	O
patients	O
with	O
previously	O
untreated	O
metastatic	O
pancreatic	O
cancer	O
.	O

In	O
this	O
context	O
,	O
based	O
on	O
the	O
phase	O
II	O
AFUGEM	O
clinical	O
trial	O
,	O
we	O
report	O
the	O
impact	O
on	O
HRQoL	O
of	O
a	O
first	O
-	O
line	O
therapy	O
combining	O
nab	O
-	O
paclitaxel	O
plus	O
either	O
[P1]	O
gemcitabine	O
[P2]	O
or	O
sLV5FU2	O
in	O
patients	O
with	O
previously	O
untreated	O
metastatic	O
pancreatic	O
cancer	O
.	O

In	O
this	O
context	O
,	O
based	O
on	O
the	O
phase	O
II	O
AFUGEM	O
clinical	O
trial	O
,	O
we	O
report	O
the	O
impact	O
on	O
HRQoL	O
of	O
a	O
first	O
-	O
line	O
therapy	O
combining	O
nab	O
-	O
paclitaxel	O
plus	O
either	O
gemcitabine	O
or	O
[P1]	O
sLV5FU2	O
[P2]	O
in	O
patients	O
with	O
previously	O
untreated	O
metastatic	O
pancreatic	O
cancer	O
.	O

Using	O
a	O
minimization	O
technique	O
stratified	O
by	O
center	O
and	O
ECOG	O
performance	O
status	O
,	O
patients	O
were	O
randomly	O
assigned	O
(	O
1:2	O
ratio	O
)	O
to	O
receive	O
[P1]	O
nab	O
-	O
paclitaxel	O
plus	O
gemcitabine	O
[P2]	O
(	O
control	O
arm	O
)	O
or	O
nab	O
-	O
paclitaxel	O
plus	O
sLV5FU2	O
(	O
experimental	O
arm	O
)	O
.	O

Using	O
a	O
minimization	O
technique	O
stratified	O
by	O
center	O
and	O
ECOG	O
performance	O
status	O
,	O
patients	O
were	O
randomly	O
assigned	O
(	O
1:2	O
ratio	O
)	O
to	O
receive	O
nab	O
-	O
paclitaxel	O
plus	O
gemcitabine	O
(	O
[P1]	O
control	O
arm	O
[P2]	O
)	O
or	O
nab	O
-	O
paclitaxel	O
plus	O
sLV5FU2	O
(	O
experimental	O
arm	O
)	O
.	O

Using	O
a	O
minimization	O
technique	O
stratified	O
by	O
center	O
and	O
ECOG	O
performance	O
status	O
,	O
patients	O
were	O
randomly	O
assigned	O
(	O
1:2	O
ratio	O
)	O
to	O
receive	O
nab	O
-	O
paclitaxel	O
plus	O
gemcitabine	O
(	O
control	O
arm	O
)	O
or	O
[P1]	O
nab	O
-	O
paclitaxel	O
plus	O
sLV5FU2	O
(	O
experimental	O
arm	O
)	O
[P2]	O
.	O

A	O
difference	O
of	O
restricted	O
mean	O
survival	O
time	O
greater	O
than	O
zero	O
favored	O
the	O
[P1]	O
sLV5FU2	O
group	O
[P2]	O
.	O

39	O
in	O
the	O
[P1]	O
gemcitabine	O
group	O
[P2]	O
and	O
75	O
in	O
the	O
sLV5FU2	O
group	O
.	O

39	O
in	O
the	O
gemcitabine	O
group	O
and	O
75	O
in	O
the	O
[P1]	O
sLV5FU2	O
group	O
[P2]	O
.	O

Sixty	O
-	O
four	O
patients	O
(	O
56.1	O
%	O
)	O
completed	O
the	O
QLQ	O
-	O
C30	O
questionnaire	O
at	O
baseline	O
,	O
22	O
patients	O
(	O
56.4	O
%	O
)	O
in	O
the	O
[P1]	O
gemcitabine	O
group	O
[P2]	O
,	O
and	O
42	O
(	O
56.0	O
%	O
)	O
in	O
the	O
sLV5FU2	O
group	O
(	O
Figure	O
1	O
)	O
.	O

Sixty	O
-	O
four	O
patients	O
(	O
56.1	O
%	O
)	O
completed	O
the	O
QLQ	O
-	O
C30	O
questionnaire	O
at	O
baseline	O
,	O
22	O
patients	O
(	O
56.4	O
%	O
)	O
in	O
the	O
gemcitabine	O
group	O
,	O
and	O
42	O
(	O
56.0	O
%	O
)	O
in	O
the	O
[P1]	O
sLV5FU2	O
group	O
[P2]	O
(	O
Figure	O
1	O
)	O
.	O

Patients	O
in	O
the	O
[P1]	O
sLV5FU2	O
group	O
[P2]	O
completed	O
the	O
questionnaire	O
longer	O
after	O
compared	O
to	O
the	O
gemcitabine	O
group	O
.	O

Patients	O
in	O
the	O
sLV5FU2	O
group	O
completed	O
the	O
questionnaire	O
longer	O
after	O
compared	O
to	O
the	O
[P1]	O
gemcitabine	O
group	O
[P2]	O
.	O

In	O
the	O
sensitivity	O
analysis	O
excluding	O
death	O
as	O
an	O
event	O
,	O
TUDD	O
results	O
were	O
significantly	O
in	O
favor	O
of	O
the	O
[P1]	O
sLV5FU2	O
group	O
[P2]	O
for	O
physical	O
functioning	O
(	O
HR	O
=	O
0.51	O
[	O
90	O
%	O
CI	O
0.27	O
-	O
0.97	O
]	O
)	O
and	O
pain	O
(	O
HR	O
=	O
0.26	O
[	O
90	O
%	O
CI	O
0.09	O
-	O
0.74	O
]	O
)	O
(	O
Table	O
S4	O
)	O
.	O

A	O
trend	O
toward	O
longer	O
TUDD	O
in	O
favor	O
of	O
the	O
[P1]	O
sLV5FU2	O
group	O
[P2]	O
among	O
all	O
other	O
dimensions	O
was	O
observed	O
,	O
except	O
for	O
constipation	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
suggests	O
that	O
nab	O
-	O
[P1]	O
paclitaxel	O
plus	O
simplified	O
leucovorin	O
and	O
fluorouracil	O
[P2]	O
does	O
not	O
have	O
a	O
negative	O
impact	O
on	O
HRQoL	O
compared	O
to	O
nab	O
-	O
paclitaxel	O
plus	O
gemcitabine	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
suggests	O
that	O
nab	O
-	O
paclitaxel	O
plus	O
simplified	O
leucovorin	O
and	O
fluorouracil	O
does	O
not	O
have	O
a	O
negative	O
impact	O
on	O
HRQoL	O
compared	O
to	O
nab	O
-	O
[P1]	O
paclitaxel	O
plus	O
gemcitabine	O
[P2]	O
.	O